Mateu-Albero, Tamara
Juárez-Sánchez, Raquel
Loscertales, Javier
Mol, Wim
Terrón, Fernando
Muñoz-Calleja, Cecilia
Cuesta-Mateos, Carlos http://orcid.org/0000-0002-1576-9790
Article History
Received: 2 February 2021
Accepted: 8 July 2021
First Online: 23 July 2021
Declarations
:
: CCM is an employee of Catapult Therapeutics and of Immunological and Medical Products (IMMED S.L.) and a shareholder in IMMED. JL has received honoraria from Abbvie, Janssen, BeiGene, and Astra-Zeneca. FT and WM are managing directors of Catapult Therapeutics, and FT is CEO of IMMED.S.L. and a shareholder in the same company and Catapult Therapeutics. CMC is a consultant for IMMED S.L., held a patent for the use of therapeutic antibodies targeting CCR7 in cancer and has received research funds from IMMED.S.L. and Catapult Therapeutics. She also holds shares in IMMED S.L. RJS is an employee of IMMED S.L. The other authors declare that they have no competing interests.
: The clinical study was performed in accordance with the principles of the Declaration of Helsinki and was approved and supervised by the Ethics Committee of Hospital Universitario de la Princesa (PI-352). Written informed consent was obtained from each patient before they entered the study.
: Written informed consent was obtained from each patient before they entered the study.